Possibilities of using Nolodatak (flupirtine) in the treatment of musculoskeletal pain syndromes


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

There is a high prevalence of musculoskeletal pain syndromes that are associated with long-term disability, worse quality of life in patients, and considerable material costs of treatment and rehabilitation; in addition, undesirable side effects can occur during pharmacotherapy. The paper considers whether Nolodatak (flupirtine) that has an analgesic, muscle relaxant, and neuroprotective effect may be used.

Full Text

Restricted Access

About the authors

O. Badalyan

N.I. Pirogov Russian National Research Medical University

Email: nevrcao@gmail.com

S. Burd

N.I. Pirogov Russian National Research Medical University

Email: nevrcao@gmail.com

A. Lebedeva

N.I. Pirogov Russian National Research Medical University

Email: nevrcao@gmail.com

References

  1. Вознесенская Т.Г. В кн.: Болевые синдромы в неврологической практике. Под ред. А.М. Вейна / М.: МЕДпресс, 1999; 217-84.
  2. Камчатнов П.Р., Батышева Т.Т., Ганжула П.А. и др. Применение катадолона у больных со спондилогенной дорсопатией // Журн. неврол. и психиат. им. С.С. Корсакова. - 2006; 106 (11): 46-9.
  3. Насонов Е.Л., Насонова В.А. Ревматология / М.: ГЭОТАР-Медиа, 2005.
  4. Насонов Е.Л., Лазебник Л.Б., Кукушкин М.Л. и др. Применение нестероидных противовоспалительных препаратов / М.: ИМА-пресс, 2009.
  5. Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих нестероидные противовоспалительные препараты: влияние стандартных факторов риска // Тер. арх. - 2008; 80 (5): 62-6.
  6. Баранцевич Е., Андреев В. Возможности лечения хронической боли при пояснично-крестцовой радикулопатии // Врач. - 2012; 11: 13-9.
  7. Насонов Е.Л., Яхно Н.Н., Каратеев А.Е. и др. Общие принципы лечения скелетно-мышечной боли. Междисциплинарный консенсус // Научно-практ. ревматол. - 2016; 54 (3): 247-65.
  8. Есин Р.Г., Лотфуллина Н.З., Есин О.Р. Цервикалгия, дорзалгия, люмбалгия. Дифференциальная диагностика, дифференцированная терапия / Казань: ИИЦ УД Президента РТ, 2015.
  9. Banerjee M., Bhattacharyya K. et al. Comparative study of efficacy and tolerability of flupirtine v.s. tramadol in non-steroidal anti-inflammatory drug intolerant mechanical low back pain // Ind. J. Rheumatol. - 2012; 7 (3): 135-40.
  10. Ueberall A., Eberhardt A., Mueller-Schwefe H. Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice // Int. J. Gen Med. - 2016; 9: 39-51.
  11. Qaseem A., Wilt T., McLean R. et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians // Ann. Intern. Med. - 2017; 166 (7): 514-30. doi: 10.7326/M16-2367.
  12. Brown D., Passmore G. Neural KCNQ (Kv7) channels // Br. J. Pharmacol. -2009; 156 (8): 1185-95.
  13. Rivera-Arconada I., Vicente-Baz J., Lopez-Garcia J. Targeting Kv7 channels in pain pathways // Oncotarget. - 2017; 8: 1254-5. doi: 10.18632/oncotarget.15261.
  14. Szelenyi I. Flupirtine, a rediscovered drug, revisited // Inflamm. Res. - 2013; 62 (3): 251-8.
  15. Fleckenstein J., Sittl R., Averbeck B. et al. Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial // J. Transl. Med. - 2013; 11: 34-9.
  16. Kornhuber J., Bleich S., Wiltfang J. et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels // J. Neural. Transm. - 1999; 106 (9-10): 857-67.
  17. Klinger F., Bajric M., Salzer I. et al. d-Subunit-containing GABAA receptors are preferred tar-gets for the centrally acting analgesic flupirtine // Br. J. Pharmacol. - 2015; 172 (20): 4946-58.
  18. Klinger F., Geier P., Dorostkar M. et al. Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine // Br. J. Pharmacol. - 2012; 166: 1631-42.
  19. Harish S., Bhuvana K., Bengalorkar M. et al. Flupirtine: Clinical pharmacology // J. Anaesthesiol. Clin. Pharmacol. - 2012; 28 (2): 172-7.
  20. Klawe C., Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound // Expert Opin. Pharmacother. - 2009; 10 (9): 1495-500.
  21. Bientinesi R., Mancuso C., Martire M. et al. KV7 channels in the human detrusor: channel modulator effects and gene and protein expression // Naunyn Schmiedebergs Arch. Pharmacol. - 2017; 390 (2): 127-37.
  22. Takagi H., Hashitani H. Effects of K+-channel openers on spontaneous action potentials in detrusor smooth muscle of the guinea-pig urinary bladder // Eur. J. Pharmacol. - 2016; 789: 179-86.
  23. Ahuja V., Mitra S., Kazal S. et al. Comparison of analgesic efficacy of flupirtine maleate and ibuprofen in gynaecological ambulatory surgeries: A randomized controlled trial // Indian J. Anaesth. - 2015; 59 (7): 411-5.
  24. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tense-ness. Results of a postmarket surveillance study // Fortschr. Med. Orig. - 2003; 121 (1): 11-8.
  25. Sampath D., Valdez R., White A. et al. Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy // Neuropharmacology. -2017; 123: 126-35 doi: 10.1016/j.neuropharm.2017.06.002.
  26. Sattler M., Williams S., Neusch C. et al. Flupirtine as Neuroprotective AddOn Therapy in Autoimmune Optic Neuritis // Am. J. Pathol. - 2008; 173 (5): 1496-507.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Russkiy Vrach Publishing House